Sub-Q Bionics Raises $1.5M for Lymphedema Treatment

Got story updates? Submit your updates here. ›

Sub-Q Bionics, a medical device company focused on developing innovative solutions for lymphedema care, has closed a $1.5 million pre-seed funding round. The company, which has operations in Stillwater, Minnesota and Tel Aviv, Israel, will use the new capital to further advance its next-generation treatment for the chronic and debilitating condition.

Why it matters

Lymphedema is a chronic and progressive condition caused by a blockage in the lymphatic system, leading to swelling, pain, and increased risk of infection. Current treatment options are limited, making Sub-Q Bionics' work to develop more effective solutions an important advancement in this underserved medical field.

The details

Sub-Q Bionics is working on a proprietary device that uses advanced materials and a novel design to provide more effective lymphatic drainage for lymphedema patients. The pre-seed funding will allow the company to accelerate product development, clinical trials, and regulatory approvals as it moves towards commercialization of its innovative treatment.

• Sub-Q Bionics closed the $1.5 million pre-seed round on March 31, 2026.

What’s next

With the new funding, Sub-Q Bionics plans to accelerate product development, clinical trials, and regulatory approvals as it works towards commercializing its next-generation lymphedema treatment.